Pathology

Cesarman, Ethel; Chadburn, Amy

doi:10.1007/978-3-319-26857-6_1

Cited by 1 publication

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the presented patient, germinal center B-cell-like (GCB) DLBCL aberrant molecular phenotype, with MUM1 and BCL6 co-expression, as well as a high expression of Ki-67, was identified immunohistochemically. There are numerous, often contradictory interpretations of the clinical significance of MUM1, BCL6, and Ki-67 expression, even more controversial in the HIV-related DLBCL [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Two-Year Complete Remission of Diffuse Large B-Cell Lymphoma in an Immunological Nonresponder HIV-Infected Patient: Case Report

Vrbić¹,

Petković

Vrbić

et al. 2017

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: HIV-infected patients are affected significantly more frequently by all types of lymphoma, with diffuse large B-cell lymphoma (DLBCL) as the most prevalent histological type. Since the introduction of combination antiretroviral therapy (cART) morbidity and mortality of DLBCL has been markedly reduced, which is primarily interpreted as a result of the drug-mediated immune reconstitution. Case Report: We present a previously healthy, 44-year-old HIV-infected man with DLBCL of the oral cavity, treated with immunochemotherapy and cART. During HIV-directed treatment, despite the successful virologic response, a satisfactory immunological response was not achieved. However, the patient had a 2-year complete remission after first-line treatment of DLBCL. Conclusion: Response to cART strongly predicts outcome in patients with DLBCL. Close monitoring of HIV-directed therapy efficacy, especially as to achievement of successful virologic response, independently associated with prolonged survival, is essential for estimating future DLBCL treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%